Viral vector (Non-replicating) vaccine · VDDBV0051
Note: 1 additional source trial listed this vaccine in studies of unrelated viruses (e.g. as a comparator, adjunct, or in coadministration trials with other vaccines). Those trials are not shown here.
| NCT ID | Phase | Disease / Condition |
|---|---|---|
| NCT04313127 | Phase 1 | COVID-19 |
| NCT04568811 | Phase 1 | COVID-19 |
| NCT04552366 | Phase 1 | COVID-19 |
| NCT04398147 | Phase 2 | COVID-19 |
| NCT04840992 | Phase 2 | COVID-19 |
| NCT05043259 | Phase 2 | COVID-19 |
| NCT04566770 | Phase 2 | COVID-19 |
| NCT05293223 | Phase 2 | COVID-19 |
| NCT04341389 | Phase 2 | COVID-19 |
| NCT05162482 | Phase 2 | COVID-19 |
| NCT05005156 | Phase 2 | COVID-19 |
| NCT04954092 | Phase 3 | COVID-19 |
| NCT04526990 | Phase 3 | COVID-19 |
| NCT04540419 | Phase 3 | COVID-19 |
| NCT05169008 | Phase 3 | COVID-19 |
| NCT04892459 | Approved | COVID-19 |
| NCT05303584 | Approved | COVID-19 |
| NCT05313646 | Approved | COVID-19 |